Stockholders' Equity - Additional Information (Detail)										6 Months Ended
	Mar. 06, 2017 shares	Sep. 28, 2016 USD ($) shares	Sep. 23, 2016 $ / shares shares	Jul. 05, 2016 USD ($) shares	Jun. 07, 2016 USD ($) Employee Tranche shares	Mar. 18, 2016 USD ($)	Jul. 22, 2015 USD ($) $ / shares shares	Apr. 04, 2015 USD ($) shares	Apr. 04, 2013 USD ($) $ / shares shares	Jun. 30, 2016 USD ($) shares	Dec. 31, 2015 shares	Jun. 30, 2015 shares
Stockholders Equity [Line Items]
Preferred stock issuable | $										$ 3,000,000
Proceeds from preferred stock issuable | $										$ 250,000
Preferred stock converted into common stock										3,413,804		1,826,317
Common stock, shares outstanding										13,242,544	13,187,544
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Common stock, shares outstanding							16,656,348			13,242,544
Increase in common stock outstanding, percentage							26.00%
Additional warrants issue to warrant holders							3,749,692
Subsequent Event [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Common stock, shares outstanding	18,778,218		14,173,544
Increase in common stock outstanding, percentage	32.00%
Additional warrants issue to warrant holders			4,823,733
Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized										40,000,000	40,000,000
Series A Convertible Preferred stock, shares outstanding										1,024	1,041
Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Effective conversion price per share | $ / shares							$ 0.30
Series A Convertible Preferred stock, shares outstanding							1,176
Stated value per share for redemption | $ / shares							$ 1,000
Preferred stock redemption period							120 days
Maximum limit on indebtedness | $							$ 250,000
Preferred stock converted into common stock							3,918,667
Additional preferred stock converted into common stock							2,092,350
Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Effective conversion price per share | $ / shares							$ 0.64
Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Minimum [Member]
Stockholders Equity [Line Items]
Effective conversion price per share | $ / shares							$ 0.30
Series A Convertible Preferred Stock [Member] | Hypothetical Conversion on Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Preferred stock converted into common stock										3,413,804
Series A Convertible Preferred Stock [Member] | Subsequent Event [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Effective conversion price per share | $ / shares			$ 0.18
Series A Convertible Preferred stock, shares outstanding	829		1,000
Stated value per share for redemption | $ / shares			$ 1,000
Preferred stock converted into common stock	4,604,674		5,554,667
Additional preferred stock converted into common stock			2,221,867
Series A Convertible Preferred Stock [Member] | Subsequent Event [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Effective conversion price per share | $ / shares			$ 0.30
Series A Convertible Preferred Stock [Member] | Subsequent Event [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Minimum [Member]
Stockholders Equity [Line Items]
Effective conversion price per share | $ / shares			$ 0.18
Pineworld Capital Limited [Member]
Stockholders Equity [Line Items]
Anti-dilution protection of equity interest					15.00%
Anti-dilution protection of post-money valuation | $					$ 20,000,000
Number of tranches | Tranche					2
Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Proceeds from preferred stock issuable | $						$ 250,000
Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member] | Second Tranche [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized					400,000
Proceeds from preferred stock issuable | $					$ 2,000,000
Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member] | Subsequent Event [Member]
Stockholders Equity [Line Items]
Proceeds from preferred stock issuable | $				$ 750,000
Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member] | Subsequent Event [Member] | Initial Tranche [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized				200,000
Proceeds from preferred stock issuable | $				$ 1,000,000
Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member] | Subsequent Event [Member] | Second Tranche [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized		400,000
Proceeds from preferred stock issuable | $		$ 2,000,000
Angionetics Inc. [Member] | Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred stock conversion basis					The Shares are initially convertible on a one to one basis into Angionetics common stock.
Percentage of stock convertible at pro rata basis					15.00%
Angionetics Inc. [Member] | Series A Convertible Preferred Stock [Member] | Subsequent Event [Member]
Stockholders Equity [Line Items]
Proceeds from preferred stock issuable | $		2,000,000
Angionetics Inc. [Member] | Pineworld Capital Limited [Member]
Stockholders Equity [Line Items]
Preferred stock issuable | $						250,000
Angionetics Inc. [Member] | Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member] | Subsequent Event [Member] | Second Tranche [Member]
Stockholders Equity [Line Items]
Proceeds from preferred stock issuable | $		$ 2,000,000
Huapont Life Sciences [Member]
Stockholders Equity [Line Items]
Revenues | $					$ 1,100,000,000
Huapont Life Sciences [Member] | Shenzhen Stock Exchange [Member]
Stockholders Equity [Line Items]
Current market capitalization | $					$ 3,000,000,000
Huapont Life Sciences [Member] | Mainland China [Member]
Stockholders Equity [Line Items]
Number of employees | Employee					7,100
Share Purchase Agreement [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Percentage of common stock issued and outstanding									10.00%
Share Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized									4,012
Proceeds from preferred stock issuable | $									$ 4,000,000
Effective conversion price per share | $ / shares									$ 0.6437
Share Purchase Agreement [Member] | Angionetics Inc. [Member] | Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Proceeds from preferred stock issuable | $						250,000
Share Purchase Agreement [Member] | Angionetics Inc. [Member] | Series A Convertible Preferred Stock [Member] | Subsequent Event [Member]
Stockholders Equity [Line Items]
Proceeds from preferred stock issuable | $				$ 750,000
Share Purchase Agreement [Member] | Angionetics Inc. [Member] | Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized					600,000
Proceeds from preferred stock issuable | $					$ 3,000,000	$ 250,000
Shenzhen Qianhai Taxus [Member]
Stockholders Equity [Line Items]
Business acquisition, date of agreement										Apr. 04, 2015
Business acquisition, purchase of number of shares								600,000
Business acquisition, purchase price | $								$ 3,000,000
Payment for business acquisition | $								$ 600,000